A New Surface
for Medicine
Introducing the Tacterra™ Platform
The Tacterra™ platform transforms the delivery of medicine. The patch, resembling an adhesive bandage, is painlessly applied using an applicator and removed after a few minutes; no sharps bin required. Once applied, each patch delivers bioactive tips into the skin. After the patch is removed, these bioactive tips dissolve into the body, rapidly releasing their payload of therapeutics.
Tacterra™ combines multiple breakthrough technologies that provide a better patient experience and improved access to transformative medicines.
Microarray Patch (MAP) in Action
Once placed on the skin, each MAP delivers a microarray of slow-release, bioactive tips into the skin. These bioactive tips rapidly dissolve into the body after the patch is removed.
Easy and Accessible
The Tacterra™ platform is designed for efficient delivery and simple, short wear time. At home, on the go, or into extreme environments — Tacterra™ enables patients to self-apply MAPs with ease. MAP delivered GLP-1 provides a better experience compared to injections without compromising efficacy.
Flexible and Consistent
Tacterra™’s biggest strengths and primary points of differentiation are consistency and flexibility. Terrestrial’s in-house GMP manufacturing accommodates variable array sizes, enabling the platform to deliver a wide range of payloads and doses. Dissolving tips delivered with an applicator allow the Tacterra™ platform to deliver doses more consistently and effectively than competition.
Refrigeration-free
The Tacterra™ platform keeps therapeutics stable at room temperature, eliminating the burden and cost associated with cold chain. This makes it less expensive to ship and store therapeutics, and easier for people to deliver or transport therapeutics while on the go — increasing access and adherence.
Molecular Versatility
Terrestrial has generated strong preclinical and clinical data, delivering a range of molecules with the Tacterra™ platform, demonstrating flexibility.
MAPs can accommodate: therapeutic peptides and proteins, adjuvanted vaccines, live viruses and virus-like particles, inactivated viruses, and mRNA.
Scalable Manufacturing
Terrestrial’s GMP facility was built to flexibly accommodate a range of molecules, large and small. The line was built to support rapid production of products into Phase I and Phase II clinical trials. Terrestrial is actively automating and scaling its manufacturing capability to enable production of millions of patches annually.